Advertisement

Topics

FDA Advisory Committee Recommends Approval of Dsuvia for the Treatment of Moderate-to-Severe Acute Pain

15:10 EDT 12 Oct 2018 | Drugs.com

REDWOOD CITY, Calif., Oct. 12, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, announced today that the...

Original Article: FDA Advisory Committee Recommends Approval of Dsuvia for the Treatment of Moderate-to-Severe Acute Pain

NEXT ARTICLE

More From BioPortfolio on "FDA Advisory Committee Recommends Approval of Dsuvia for the Treatment of Moderate-to-Severe Acute Pain"

Advertisement
Quick Search
Advertisement
Advertisement